Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 2, 2009, Pages 361-369

  Ishida, Takanori ^a   Kiba, Takayoshi ^b   Takeda, Motohiro ^a   Matsuyama, Kotone ^b,c   Teramukai, Satoshi ^b,c   Ishiwata, Ryota ^b   Masuda, Norikazu ^d   Takatsuka, Yuichi ^e   Noguchi, Shinzaburo ^f   Ishioka, Chikashi ^g   Fukushima, Masanori ^b,c   Ohuchi, Noriaki ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Translational Research Informatics Center   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e KANSAI ROSAI HOSPITAL   (Japan)

^f OSAKA UNIVERSITY   (Japan)

^g TOHOKU UNIVERSITY   (Japan)

Author keywords

Capecitabine; Metastatic breast caner; Phase II study; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; EDEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERCALCEMIA; HYPOALBUMINEMIA; LEUKOPENIA; LIVER DYSFUNCTION; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349253032     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0882-8     Document Type: Article

References (28)

1. M Ueno T Kiba T Nishimura 2007 Changes in survival during the past two decades for breast cancer at the Kyoto University Hospital Eur J Surg Oncol 33 696 699 (Pubitemid 47029674)
2. F Petrelli M Cabiddu ME Cazzaniga 2008 Targeted therapies for the treatment of breast cancer in the post-trastuzumab era Oncologist 13 373 381
3. S Beslija J Bonneterre H Burstein 2007 Second consensus on medical treatment of metastatic breast cancer Ann Oncol 18 215 225 (Pubitemid 46323085)
4. NT Ueno AU Buzdar SE Singletary 1997 Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center Cancer Chemother Pharmacol 40 321 329 (Pubitemid 27276136)
5. CD Berg SM Swain 1994 Results of concomitantly administered chemoradiation for locally advanced noninflammatory breast cancer Semin Radiat Oncol 4 226 235 (Pubitemid 24312243)
6. http://www.uptodate.com/patients/content/topic.do?topicKey=cancer/2904
7. NE Hynes DF Stern 1994 The biology of erbB-2/neu/HER-2 and its role in cancer Biochim Biophys Acta 1198 165 184
8. F Revillion J Bonneterre JP Peyrat 1998 ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34 791 808 (Pubitemid 28248487)
9. JL Blum SE Jones AU Buzdar 1999 Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 485 493 (Pubitemid 29075232)
10. JL Blum V Dieras PM Lo Russo 2001 Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 1759 1768 (Pubitemid 32952493)
11. P Reichardt G Von Minckwitz PC Thuss-Patience 2003 Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 1227 1233 (Pubitemid 37039048)
12. P Fumoleau R Largillier C Clippe 2004 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 536 542 (Pubitemid 38220770)
13. G Schaller I Fuchs T Gonsch 2007 Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes J Clin Oncol 25 3246 3250 (Pubitemid 47325608)
14. T Osako Y Ito S Takahashi 2008 Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer Cancer Chemother Pharmacol 62 159 164
15. R Bartsch C Wenzel G Altorjai 2007 Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer J Clin Oncol 25 3853 3858 (Pubitemid 47477260)
16. 2 in patients with metastatic breast cancer according to the status of anthracycline resistance J Clin Oncol 19 336 342 (Pubitemid 32112844)
17. http://ctep.cancer.gov/forms/CTCv20-4-30-992.pdf
18. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
19. T Burzykowski M Buyse MJ Piccart-Gebhart 2008 Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer J Clin Oncol 26 1987 1992
20. CH Smorenburg M Bontenbal C Seynaeve 2001 Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane Breast Cancer Res Treat 66 83 87 (Pubitemid 32397946)
21. F Tas N Guney D Derin 2008 Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer Invest New Drugs 26 363 368
22. CX Ma P Steen KM Rowland 2006 A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study Ann Oncol 17 226 231 (Pubitemid 43160110)
23. JA O'Shaughnessy S Vukelja T Marsland 2004 Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer Clin Breast Cancer 5 142 147 (Pubitemid 39029207)
24. G Minckwitz C Zielinski E Maarteense 2008 Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05) J Clin Oncol 26 1025a
25. L Xu S Song J Zhu 2004 Results of a phase II trial of Herceptin plus Xeloda in patients with previously untreated HER2-positive metastatic breast cancer Breast Cancer Res Treat 88 suppl 1 S128
26. B Reigner T Watanabe J Schüller 2003 Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer Cancer Chemother Pharmacol 52 193 201 (Pubitemid 37204532)
27. T Watanabe N Katsumata Y Sasaki 1991 A multicenter phase II Trial of Xeloda™ (Capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer Proc Am Soc Clin Oncol 20 1991a
28. http://www.clinicaltrials.gov